Residency · Residency · Ophthalmology
Thyroid Eye Disease: Pathogenesis and Modern Management
Introduction
Thyroid eye disease (TED), also known as Graves orbitopathy, is the most common cause of proptosis in adults. It is an autoimmune inflammatory condition targeting orbital tissues, primarily extraocular muscles and orbital fat. Recent breakthroughs in understanding pathogenesis have led to targeted biologic therapies that are transforming management.
Epidemiology
Affects approximately 25-50% of patients with Graves disease. Female predominance (5:1), but males tend to have more severe disease. Peak onset: 40-60 years of age. Smoking is the most significant modifiable risk factor, increasing severity 7-8 fold. Can occur with hypothyroidism, euthyroidism, or Hashimoto thyroiditis (euthyroid Graves)
Pathogenesis
Autoimmune Mechanisms
TSH receptor (TSH-R) autoantibodies bind receptors on orbital fibroblasts. IGF-1 receptor (IGF-1R) forms a physical and functional complex with TSH-R on orbital fibroblasts. Activated orbital fibroblasts differentiate into adipocytes and produce hyaluronan (glycosaminoglycans) Resultant tissue expansion causes proptosis, extraocular muscle enlargement, and orbital congestion. CD4+ T-cell infiltration and cytokine release (IL-6, IL-16, TNF-alpha) amplify inflammation.
Rundle Curve
TED follows a self-limited course described by Rundle's curve. Active inflammatory phase (12-24 months) followed by a stable fibrotic phase. Therapeutic intervention is most effective during the active phase.
Clinical Features
Signs and Symptoms
Lid retraction -- most common sign (present in >90%); Dalrymple sign. Proptosis -- Hertel exophthalmometry; asymmetric in 10-15%. Restrictive strabismus -- inferior rectus most commonly affected, causing hypotropia and diplopia. Periorbital edema, chemosis, conjunctival injection. Lid lag (von Graefe sign) on downgaze. Compressive optic neuropathy -- occurs in 3-5%; may present without significant proptosis ("lipogenic" variant)
Clinical Activity Score (CAS)
Seven-point scoring system (active if >= 3/7):
| Point | Finding |
|---|---|
| 1 | Spontaneous retrobulbar pain |
| 2 | Pain on eye movement |
| 3 | Eyelid erythema |
| 4 | Conjunctival redness |
| 5 | Chemosis |
| 6 | Swelling of caruncle or plica |
| 7 | Eyelid edema |
Imaging
CT orbit (axial and coronal): fusiform extraocular muscle enlargement with tendon sparing, increased orbital fat volume, apical crowding. MRI orbit: T2-weighted sequences differentiate active edematous muscle (hyperintense) from chronic fibrotic muscle (hypointense)
Management
Medical Therapy
Smoking cessation -- critical first step. Selenium supplementation (100 mcg twice daily) -- shown to improve mild TED in EUGOGO trial. Intravenous methylprednisolone -- standard for moderate-to-severe active TED (cumulative dose not exceeding 8 g) Mycophenolate mofetil -- steroid-sparing agent with evidence from EUGOGO trials. Teprotumumab -- anti-IGF-1R monoclonal antibody; FDA-approved 2020; significant reduction in proptosis and CAS in OPTIC trial. Tocilizumab -- anti-IL-6R antibody; second-line biologic option.
Surgical Rehabilitation (Sequential Approach)
Performed after disease stabilization (inactive phase):
Orbital decompression -- for persistent proptosis or compressive optic neuropathy (balanced medial/lateral wall approach preferred) Strabismus surgery -- adjustable sutures; large recessions on tight muscles. Eyelid surgery -- retraction repair (Muller muscle excision, lower lid spacer grafts), blepharoplasty.
Emergent Management
Compressive optic neuropathy: high-dose IV steroids; urgent orbital decompression if no response within 1-2 weeks. Corneal decompensation from severe proptosis: aggressive lubrication, tarsorrhaphy, decompression.
Key Clinical Pearls
TED can occur without hyperthyroidism; always consider the diagnosis in unexplained proptosis or strabismus. Compressive optic neuropathy may occur without severe proptosis due to apical fat expansion. Teprotumumab has revolutionized medical management but carries risks including hearing loss and hyperglycemia. Surgical rehabilitation follows a strict sequence: decompression, then strabismus, then eyelid surgery. Radioactive iodine therapy may worsen TED; concurrent steroid prophylaxis is recommended.
References
- Douglas RS, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382(4):341-352.
- Bartalena L, et al. The 2021 European Group on Graves' Orbitopathy (EUGOGO) clinical practice guidelines. Eur J Endocrinol. 2021;185(4):G43-G67.
- Smith TJ, Hegedus L. Graves' disease. N Engl J Med. 2016;375(16):1552-1565.
- Rootman DB. Orbital decompression for thyroid eye disease. Surv Ophthalmol. 2018;63(1):86-104.